3rd Apr 2006 10:15
Hikma Pharmaceuticals Plc03 April 2006 3 April 2006 Block Listing of Shares Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC (the "Company") announces that it has made a blocklisting application to the UK Listing Authority and the London Stock Exchangefor a total of 4,058,400 ordinary shares of 10p each in the capital of theCompany to be admitted to the Official List of the UK Listing Authority andadmitted to trading on the main market of the London Stock Exchange. The shares, when issued, will be issued fully paid and rank pari passu in allrespects with the existing issued ordinary shares of the Company. The sharesmay be issued pursuant to the exercise of options under the HikmaPharmaceuticals PLC 2004 Stock Option Plan (the "Plan"). Participants in thePlan have or will become entitled to these shares following the vesting andexercise of options over shares. It is expected that admission will be granted on 4 April 2006. For further information, please contact: Henry Knowles, Company SecretaryHikma Pharmaceuticals PLC +44 20 7479 4870 Susan Ringdal, Investor Relations Director Hikma Pharmaceuticals PLC +44 20 7479 4893 About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals